The U.S. Food and Drug Administration just approved Biogen’s new Alzheimer’s drug Aducanumab, a historic move as it is the first new therapy for the disease in nearly two decades. The drug will be marketed under the name Aduhelm and is expected to generate billions of dollars in revenue for Biogen. Dr. Jason Karlawish, co-director of the University of Pennsylvania Medical Center, discusses the new Alzheimer’s drug, saying that the evidence to approve the drug “was not sufficient.” U.S. law enforcement officials said Monday they were able to recover $2.3 million in bitcoin paid to a criminal cybergroup involved in the crippling ransomware attack on Colonial Pipeline. NBC’s Ken Dilanian reports the FBI won’t reveal how it cracked the ransomware gang’s bitcoin account. CNBC’s Ylan Mui discusses the Senate’s agenda, including assignments relating to the wage gap, voting rights and judicial nominations. The Senate is also set to pass an industrial policy bill to counter China.